Preoperative Anaemia Tracks with Worse Recovery After Total Hip Arthroplasty
Anaemia before total hip arthroplasty has emerged as a consistent marker of postoperative risk, and the signal is broad rather than narrow. In the review by Chen Z., lower baseline haemoglobin was associated with greater blood loss, more transfusions, longer hospital stay, and a higher burden of complications after total hip arthroplasty. The pattern is clinically important because THA continues to expand as a procedure, and perioperative optimization has become central to improving recovery and limiting avoidable harm.
One sentence captures the practical problem. Patients who begin surgery already anaemic tend to move through a more fragile perioperative course.
The association is biologically plausible. Reduced red cell reserve limits tolerance of operative blood loss, while the need for transfusion can expose patients to additional risks, including volume overload, transfusion reactions, and downstream delays in mobilization. In joint replacement, where early rehabilitation matters, even modest haemoglobin drops can affect stamina, participation in physiotherapy, and the pace of discharge planning. Anaemia may also coexist with inflammation, malnutrition, renal dysfunction, or occult disease, each of which can amplify surgical vulnerability.
Why Anaemia Matters Before the First Incision
The review frames anaemia as more than a laboratory abnormality. In the THA setting, it functions as a preoperative risk marker that can identify patients who may need closer evaluation before entering the operating room. Screening allows clinicians to look for iron deficiency, chronic kidney disease, inflammatory disease, nutritional deficits, or other correctable drivers. When a reversible cause is found, treatment may improve haemoglobin concentration before surgery and reduce the probability of avoidable transfusion.
Yet the review stops short of treating correction as a proven outcome-improving intervention. That caution is important. Most of the evidence base linking anaemia to poorer THA outcomes comes from observational studies, which can identify associations but cannot separate cause from correlation with certainty. A patient who is anaemic may also be older, frailer, and more medically complex. In that setting, anaemia can reflect a broader burden of illness rather than act as the sole driver of poor surgical recovery.
Blood Conservation and Patient Optimization Remain Central
The review supports a holistic perioperative approach. Identification of anaemia should be paired with efforts to clarify its cause, correct reversible abnormalities when possible, and apply blood-conservation strategies during surgery. Those strategies are especially relevant in THA, where perioperative blood loss has direct consequences for transfusion exposure and length of stay. A structured pathway can also standardize decisions about iron repletion, timing of surgery, and thresholds for concern when haemoglobin is low.
Some of the strongest clinical implications sit at the bedside rather than in the abstract. If preoperative anaemia is missed, the team may encounter avoidable haemodynamic instability after surgery, a greater need for donor blood, and slower postoperative rehabilitation. If it is recognized early, the pathway can shift from reactive transfusion to proactive optimization.
The Evidence Gap Around Correction of Anaemia
The sharpest unresolved question is not whether anaemia correlates with worse outcomes, but whether correcting it before surgery changes the outcomes that matter most to patients. The review states that high-quality data remain lacking for endpoints such as functional recovery, implant survival, and mortality. Without randomized controlled trials, it remains difficult to know whether treatment of anaemia itself improves the course after THA or simply identifies patients who are already at higher risk.
This gap matters because the label “modifiable risk factor” carries clinical weight. A true modifiable risk factor should respond to intervention in a way that measurably improves patient-centred outcomes. For anaemia in THA, that proof is not yet secure. The current evidence is strong for risk stratification and weaker for claims of downstream benefit from correction alone.
Observational Data Point to Risk, Not Mechanism Alone
Observational cohorts are useful because they reflect real surgical practice, but they also carry confounding. Patients with anaemia may differ from non-anaemic patients in age, comorbidity load, renal function, nutritional status, or baseline physiologic reserve. Each of those factors can influence postoperative recovery independently. As a result, anaemia may sit at the intersection of several adverse pathways rather than operate as a single isolated cause.
The practical consequence is a more careful form of preoperative medicine. Surgeons, anaesthesiologists, and perioperative teams need to treat anaemia as a warning sign, not a standalone diagnosis. Evaluation should be systematic, and treatment decisions should be tailored to the suspected cause and the urgency of surgery.
What Still Needs to Be Proven in THA Patients
Future research needs to move beyond association and into intervention. Randomized controlled trials are needed to determine whether preoperative correction of anaemia improves recovery, reduces complications, shortens hospitalization, or affects longer-term outcomes after THA. Trials should also help clarify whether benefits differ by cause of anaemia, severity, age, or comorbidity profile.
Implementation issues are just as relevant as biology. Even when a treatment pathway exists, delays in screening, incomplete workups, and inconsistent preoperative optimization can limit its effect in routine practice. The review points to that gap directly: evidence-based management will depend not only on proving benefit, but also on building systems that reliably identify anaemia early enough for intervention.
For now, the clinical message is narrow and firm. Preoperative anaemia is a reliable predictor of poorer outcomes after total hip arthroplasty, and it should trigger systematic assessment before surgery. Whether correction changes functional recovery, implant survival, or mortality still requires proof from stronger trials.